Johnson & Johnson (JNJ)
JNJ (NYSE:Drugs)
$88.09
+0.64
+0.73%
Today's Range: 87.41 - 88.20 |
JNJ Avg Daily Volume: 9,694,500
| Last Update: 05/17/13 - 4:02 PM EDT |
| Volume: 11,439,498 |
| YTD Performance: 25.66%
|
| Open: $87.47 |
| Previous Close: $87.45 |
| 52 Week Range: $61.71 -
$88.20 |
| Oustanding Shares: 2,808,886,962 |
| Market Cap: 245,637,164,827 |
6-Month Chart
TheStreet Ratings Grade for JNJ
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
9 |
9 |
11 |
11 |
| Moderate Buy |
2 |
2 |
2 |
2 |
| Hold |
8 |
8 |
7 |
8 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.95 |
1.95 |
1.80 |
1.86 |
| Latest Dividend: |
0.66 |
| Latest Dividend Yield: |
3.02% |
| Dividend Ex-Date: |
05/23/13 |
| Price Earnings Ratio: |
23.83 |
|
| Price Earnings Comparisons: |
| JNJ |
Sector Avg. |
S&P 500 |
| 23.83 |
23.80 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
15.66%
|
38.62%
|
37.90%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
3.40 |
0.09 |
0.03 |
| Net Income |
0.00 |
0.00 |
0.00 |
| EPS |
10.60 |
-0.11 |
-0.04 |
| Earnings for JNJ: |
| EBITDA |
20.70B |
| Revenue |
67.22B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.40 |
$1.33 |
$5.42 |
$5.78 |
| Number of Analysts |
10 |
10 |
16 |
13 |
| High Estimate |
$1.43 |
$1.35 |
$5.50 |
$6.02 |
| Low Estimate |
$1.38 |
$1.31 |
$5.38 |
$5.61 |
| Prior Year |
$1.30 |
$1.25 |
$5.10 |
$5.42 |
| Growth Rate (Year over Year) |
7.77% |
6.24% |
6.20% |
6.63% |
| May 10, 2013 | 10:40 AM EDT
You can't get away from the need for good yield in an era of commodity inflation.
| May 06, 2013 | 3:53 PM EDT
How much to buy?
| May 01, 2013 | 12:49 PM EDT
Focusing on near-term drug stock earnings is the wrong move.
| Apr 26, 2013 | 12:55 PM EDT
You're better off with a third direct-selling name.
| Apr 25, 2013 | 3:55 PM EDT
How much to sell?
Apr 25, 2013 | 7:00 AM EDT
Johnson & Johnson Annual Shareholder Meeting - 10AM
| Apr 17, 2013 | 3:15 PM EDT
The bane of a management's existence.
| Apr 16, 2013 | 11:07 AM EDT
Only the most consistent companies in the world can say anything good.
| Apr 16, 2013 | 7:28 AM EDT
My current expectation is for an initial test of the mid-1550s to be faded.
| Apr 15, 2013 | 1:00 PM EDT
Don't try to grab a trade ahead of earnings.
